Skip to main content

Advertisement

Table 1 Patients characteristics

From: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

No. of patients 27
Median age [range], years 61.4 [47.6 - 74.1]
Gender  
Male 15 (55.6%)
Female 12 (44.4%)
ECOG performance status score  
0 5 (18.5%)
1 7 (25.9%)
2 9 (33.3%)
3 3 (11.1%)
Unknown 3 (11.1%)
First line chemotherapy  
FOLFIRI.3 alternating with Gemcitabine 7 (25.9%)
Gemcitabine 20 (74.1%)
Pancreatic tumor location  
Head 14 (51.8%)
Body 6 (22.2%)
Tail 6 (22.2%)
Multicentric 1 (3.7%)
Metastatic sites  
Liver 20 (74.1%)
Peritoneum 8 (29.6%)
Lung 6 (22.2%)
Distant lymph nodes 2 (7.4%)
No. of metastatic sites involved  
1 19 (70.4%)
2 7 (25.9%)
≥ 3 1 (3.7%)
Baseline CA 19–9 level  
≤ 37 UI/ml* 2 (7.4%)
> 37 UI/ml 19 (70.4%)
Unknown 6 (22.2%)
No. of cycle  
Mean 6
Median [range] 4 [1–28]
  1. Abbrevations: ECOG Eastern Cooperative Oncology Group;
  2. *upper limit of normal value.